News & Features
|
Genentech at ASCO 2008
|
||
|
Accelerated Approval for Avastin in Breast Cancer
|
||
DNA NYSE: Quote: 69.15 | Change: -1.05 | 05.20.08 | 14:27:00
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
Patient Access >>
Genentech is committed to making sure price is not a barrier to access for patients.
Awards and
Recognition >>
FORTUNE magazine has named Genentech to its "100 Best Companies to Work For" and "America's Most Admired" lists.
Postdoc Program >>
Genentech's postdoctoral program offers the chance to do cutting-edge research in an inspiring environment.

